Mounjaro vs Zepbound: What's the Difference?
If you have been researching weight loss medications, you have probably come across both Mounjaro and Zepbound. The two names appear in different contexts, sometimes described as competing drugs and s
In this article
*This article is for informational purposes only. It is not medical advice. Speak with a licensed healthcare provider before starting any new medication or treatment program.*
---
If you have been researching weight loss medications, you have probably come across both Mounjaro and Zepbound. The two names appear in different contexts, sometimes described as competing drugs and sometimes as alternatives, which understandably creates confusion.
Here is the short answer: Mounjaro and Zepbound are the same medication. Both contain tirzepatide as their active ingredient and are manufactured by Eli Lilly. The difference is regulatory. The FDA approved each product for a distinct indication. Understanding that distinction helps clarify which one you might qualify for, what it will cost, and why compounded tirzepatide is increasingly part of this conversation.
---
What Is Mounjaro?
Mounjaro is a brand-name prescription medication approved by the FDA in May 2022 for adults with type 2 diabetes. Its active ingredient is tirzepatide. Mounjaro is prescribed alongside diet and exercise to improve blood sugar control in adults whose diabetes is not adequately managed with other medications.
Mounjaro is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all given as a once-weekly subcutaneous injection. Patients typically start at 2.5 mg and increase gradually based on tolerability and treatment response.
The name "Mounjaro" is a brand name Eli Lilly registered specifically for the diabetes indication. The active ingredient is tirzepatide.
---
What Is Zepbound?
Zepbound is the same tirzepatide formulation, approved by the FDA in November 2023 for chronic weight management. Zepbound is indicated for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related health condition such as high blood pressure, type 2 diabetes, or sleep apnea.
The doses are identical to Mounjaro: 2.5 mg through 15 mg once weekly.
Eli Lilly sought and received a separate FDA approval for tirzepatide for weight management, which allowed the company to market the drug under a new brand name with labeling and FDA authorization for that specific purpose. Same molecule, different approval pathway.
---
Quick Comparison
| Mounjaro | Zepbound | |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA indication | Type 2 diabetes | Obesity / weight management |
| FDA approval date | May 2022 | November 2023 |
| Dose range | 2.5 to 15 mg/week | 2.5 to 15 mg/week |
| Mechanism | GLP-1 + GIP dual agonist | GLP-1 + GIP dual agonist |
| Manufacturer | Eli Lilly | Eli Lilly |
| Estimated cost (no insurance) | ~$1,000–$1,300/month | ~$1,000–$1,300/month |
How Tirzepatide Works
Whether the label says Mounjaro or Zepbound, the pharmacology is identical.
Tirzepatide activates two hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Most GLP-1 medications, including semaglutide (Ozempic, Wegovy), activate only the GLP-1 receptor. Tirzepatide's simultaneous action on both receptors is why researchers describe it as a "twincretin."
GLP-1 reduces appetite, slows gastric emptying, and stimulates insulin release after meals. GIP is a separate gut hormone involved in energy metabolism and fat storage. Activating both pathways together produces greater appetite suppression and metabolic effects than either hormone alone.
In the SURMOUNT-1 trial, published in the *New England Journal of Medicine* in 2022, adults with obesity or overweight (without diabetes) using tirzepatide 15 mg for 72 weeks lost an average of 20.9% of their body weight, compared to 3.1% in the placebo group. Both groups received counseling on diet and physical activity ([PMID: 35658024](https://pubmed.ncbi.nlm.nih.gov/35658024/)).
In the SURPASS-2 trial, published in 2021, tirzepatide demonstrated superior blood sugar reduction compared to weekly semaglutide in adults with type 2 diabetes, with meaningful weight loss as an additional benefit ([PMID: 34170647](https://pubmed.ncbi.nlm.nih.gov/34170647/)).
These results are for the branded, FDA-approved formulation studied in controlled clinical trials. Compounded tirzepatide has not been separately studied in equivalent trials, and branded trial results should not be assumed to apply to compounded formulations.
---
The Real Differences: Indication, Insurance, and Off-Label Use
Since the molecule is identical, the practical differences between Mounjaro and Zepbound come down to your diagnosis, your insurance plan, and how your provider navigates both.
Insurance coverage
Insurance plans follow FDA-approved indications. A plan that covers Mounjaro for type 2 diabetes management may not cover it for weight loss, because that is not Mounjaro's labeled indication. Zepbound, with its obesity approval, opens a separate coverage pathway for patients whose primary goal is weight management and who meet the BMI criteria.
Your coverage depends on your diagnosis code, not just the drug name on the prescription.
Off-label prescribing
Some providers prescribe Mounjaro off-label for weight management, particularly in patients who also have prediabetes, metabolic syndrome, or other insulin-resistance-related conditions. Off-label prescribing is legal and common in medicine. However, off-label prescriptions are less likely to receive insurance coverage, and out-of-pocket cost becomes the barrier.
Cost without insurance
Without insurance coverage, both Mounjaro and Zepbound cost approximately $1,000 to $1,300 per month for a four-week supply. Eli Lilly offers savings card programs that can reduce cost for eligible patients, but income limits and enrollment restrictions apply. Many people find these programs either difficult to navigate or unavailable for their situation.
---
Which One Is Right for You?
The answer depends on your diagnosis, your BMI, and your insurance situation.
If you have type 2 diabetes: Mounjaro is the labeled option, and your insurer is more likely to cover it under a diabetes diagnosis code.
If your primary goal is weight management: Zepbound is the labeled option, provided you meet the BMI criteria (30 or higher, or 27 or higher with a qualifying condition).
If your provider recommends tirzepatide but neither product is covered or cost is prohibitive: Compounded tirzepatide is a legal and significantly more affordable alternative to discuss with your provider.
Your prescriber can help determine which path makes sense given your health history, diagnoses, and insurance coverage.
---
Compounded Tirzepatide: The Affordable Alternative
Compounded tirzepatide is prepared by licensed 503A pharmacies on a per-patient basis when a licensed prescriber documents a specific clinical need, such as a dose not commercially available or a documented intolerance to an inactive ingredient in the brand-name product.
Important disclaimer: Compounded tirzepatide is not FDA-approved and is not the same as Mounjaro or Zepbound. It has not been studied in independent clinical trials equivalent to those conducted for the branded products. The SURMOUNT-1 and SURPASS-2 results reflect the branded formulations and should not be assumed to apply to compounded tirzepatide. Individual results vary.
That said, the cost difference is meaningful. Compounded tirzepatide through a telehealth platform typically costs $200 to $400 per month, compared to $1,000 to $1,300 for branded products without insurance.
Prescriva works with licensed 503A compounding pharmacies operating in full compliance with applicable federal and state requirements. All prescriptions are issued by licensed healthcare providers following a clinical assessment.
> Regulatory note: The FDA declared the tirzepatide shortage resolved in 2024. As of 2026, tirzepatide is no longer on the FDA drug shortage list. Under current requirements, 503A pharmacies may still lawfully prepare compounded tirzepatide for an individual patient when a licensed prescriber documents a specific clinical need not met by commercially available products. Verify current availability and regulatory status with your provider before starting treatment.
---
Getting Started with Tirzepatide Online
If you are interested in tirzepatide and want to understand your options, the telehealth process at Prescriva typically involves:
- Completing an online health assessment reviewed by a licensed provider
- A clinical review of your health history, goals, and eligibility
- A prescription, if clinically appropriate, sent to a licensed compounding pharmacy
- Monthly medication delivered to your home
---
Related Reading
- [Compounded Tirzepatide: Benefits, Cost, and How to Get It](/resources/compounded-tirzepatide-guide)
- [Mounjaro vs Ozempic vs Wegovy: Full 2026 Comparison](/resources/mounjaro-vs-ozempic-vs-wegovy-2026)
- [Compounded Tirzepatide Cost 2026](/resources/compounded-tirzepatide-cost-2026)
Important Disclaimers
Compounding Disclaimer: Compounded tirzepatide is not an FDA-approved medication. Compounded drugs are not reviewed by the FDA for safety, efficacy, or quality. Compounded tirzepatide is not the same as, equivalent to, or interchangeable with FDA-approved tirzepatide products (Mounjaro, Zepbound). Clinical trial data cited in this article (SURMOUNT-1, SURPASS-2) refers to FDA-approved branded tirzepatide formulations and may not reflect outcomes from compounded tirzepatide.
Results Disclaimer: Individual results vary. Weight management and blood-sugar outcomes depend on adherence to your prescribed treatment plan, diet, exercise, starting weight, and other individual health factors. Results are not guaranteed.
Provider Disclaimer: All medical services, including prescribing, are provided by independently licensed healthcare providers. Blue Oak Services LLC dba Prescriva is a management services organization and does not practice medicine or make clinical decisions.
Brand Disclaimer: Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Prescriva is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.
Regulatory Disclaimer: FDA regulations regarding compounded tirzepatide have evolved following the FDA's resolution of the tirzepatide shortage. Verify current availability and regulatory status with your provider before starting treatment.
---
*This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.*
Stay informed
Weekly research updates and health guides. No spam.
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →Continue reading
Semaglutide Nausea: Why It Happens and How to Manage It
Does Semaglutide Cause Thyroid Cancer? What the Research Actually Shows
